


# Virginia Neonatal Abstinence Syndrome Active Case Reporting

Year to Date Reporting Summary  
January 1, 2022 through September 30, 2022

<b>Total NAS Cases Reported†</b>	<b>48</b>
Missing	0
In State	123
Out of State	11
<b>Sex of Infant†</b>	
Missing	0
Females	67
Males	67
Unknown	0
<b>Race/Ethnicity of Infant†</b>	
Missing	19
Black/African American	18
White	80
Other	0
Unknown	7
<b>Severity of NAS Signs</b>	
Mild signs requiring non-pharmacologic treatment	70
Severe clinical signs requiring pharmacotherapy	64
<b>Other Supportive Elements for Diagnosis‡</b>	
Maternal history of substances known to cause NAS	121
Positive maternal screening test for substances known to cause NAS	93
Positive neonatal screening test for substances known to cause NAS	100
No other supportive elements for diagnosis	2

<b>Source of Exposure‡</b>	
Medication-assisted treatment (MAT)	101
Legal prescription of opioid pain reliever	3
Legal prescription of a non-opioid	9
Prescription opioid obtained without prescription	27
Non-opioid prescription obtained without prescription	8
Heroin	13
Other non-prescription substance (e.g. illicit drugs other than heroin)	50
No known exposure but clinical signs consistent with NAS	45
Other (e.g. SSRIs, another drug used in the polysubstance instances)	11



†Data is reported as missing here if the clinician filing the case report omitted a response to this field in the data collection form.

‡More than one option may have been selected, so totals may sum to >100% of overall case total.

Note: Cases in system where reporter indicated that there were no signs or symptoms of withdrawal were omitted from this case report, as they do not meet the standard case definition in use.

\*This report includes data recorded as of November, 14 2022